{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:37:03Z","timestamp":1790638623117,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","award":["ZIAMH002468-25"],"award-info":[{"award-number":["ZIAMH002468-25"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.expneurol.2016.04.003","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T20:51:34Z","timestamp":1460580694000},"page":"81-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease"],"prefix":"10.1016","volume":"281","author":[{"given":"Gabriel R.","family":"Linares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Tso","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Scheuing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Mei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Maric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Maw","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2016.04.003_bb0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/mt.2013.199","article-title":"Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors","volume":"22","author":"Balyasnikova","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/10717544.2014.880860","article-title":"Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease","volume":"22","author":"Bhatt","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0015","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/1389450114666131124140704","article-title":"Current therapeutic advances in patients and experimental models of Huntington's disease","volume":"15","author":"Brett","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0025","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s11095-012-0915-1","article-title":"Intranasal treatment of central nervous system dysfunction in humans","volume":"30","author":"Chapman","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0030","doi-asserted-by":"crossref","first-page":"586586","DOI":"10.4061\/2011\/586586","article-title":"Detection of intranasally delivered bone marrow-derived mesenchymal stromal cells in the lesioned mouse brain: a cautionary report","volume":"2011","author":"Chartoff","year":"2011","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharmthera.2010.07.006","article-title":"Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders","volume":"128","author":"Chiu","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0040","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/npp.2011.128","article-title":"Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease","volume":"36","author":"Chiu","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.111.005512","article-title":"Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder","volume":"65","author":"Chiu","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.tins.2009.06.002","article-title":"Multiple roles of HDAC inhibition in neurodegenerative conditions","volume":"32","author":"Chuang","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejcb.2009.02.001","article-title":"Intranasal delivery of cells to the brain","volume":"88","author":"Danielyan","year":"2009","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/rej.2010.1130","article-title":"Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease","volume":"14","author":"Danielyan","year":"2011","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0070","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051253","article-title":"Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement","volume":"8","author":"Donega","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.expneurol.2010.03.005","article-title":"Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease","volume":"224","author":"Ebert","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2202-13-97","article-title":"Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6\/2 transgenic mouse model of Huntington's disease","volume":"13","author":"El-Akabawy","year":"2012","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0090","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0095","doi-asserted-by":"crossref","first-page":"C896","DOI":"10.1152\/ajpcell.00439.2010","article-title":"Anti-inflammatory cytokine interleukin-19 inhibits smooth muscle cell migration and activation of cytoskeletal regulators of VSMC motility","volume":"300","author":"Gabunia","year":"2011","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0100","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.neuron.2015.01.008","article-title":"N17 modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice","volume":"85","author":"Gu","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1096\/fj.05-4551fje","article-title":"Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging","volume":"20","author":"Krishnan","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/mp.2013.192","article-title":"FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers","volume":"20","author":"Leng","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-1-61779-815-3_10","article-title":"Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseases","volume":"879","author":"Lescaudron","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0120","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1152\/ajpendo.00065.2011","article-title":"Role of diabetes- and obesity-related protein in the regulation of osteoblast differentiation","volume":"301","author":"Linares","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0125","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0130","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1007\/s12035-013-8585-5","article-title":"IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice","volume":"49","author":"Lopes","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington's disease","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/089771504772695922","article-title":"Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury","volume":"21","author":"Mahmood","year":"2004","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/scrt53","article-title":"Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia","volume":"2","author":"McGinley","year":"2011","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","article-title":"Insights into direct nose to brain delivery: current status and future perspective","volume":"21","author":"Mittal","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0155","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/hmg\/ddq512","article-title":"Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice","volume":"20","author":"Mughal","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0160","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2004.07.011","article-title":"Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice","volume":"17","author":"Norflus","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0165","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","article-title":"Choosing an animal model for the study of Huntington's disease","volume":"14","author":"Pouladi","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010611","article-title":"Systematic comparison of constitutive promoters and the doxycycline-inducible promoter","volume":"5","author":"Qin","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0175","doi-asserted-by":"crossref","first-page":"866","DOI":"10.5966\/sctm.2012-0045","article-title":"Intranasal delivery of neural stem\/progenitor cells: a noninvasive passage to target intracerebral glioma","volume":"1","author":"Reitz","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0180","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1523\/JNEUROSCI.5686-11.2012","article-title":"Minocycline-preconditioned neural stem cells enhance neuroprotection after ischemic stroke in rats","volume":"32","author":"Sakata","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004962","article-title":"Neuroendocrine disturbances in Huntington's disease","volume":"4","author":"Saleh","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0190","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.7150\/ijbs.9898","article-title":"Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?","volume":"10","author":"Scheuing","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018711","article-title":"The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS","volume":"6","author":"Scranton","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0205","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","article-title":"A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington's disease","volume":"33","author":"Simmons","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0210","doi-asserted-by":"crossref","first-page":"11109","DOI":"10.1523\/JNEUROSCI.0895-12.2012","article-title":"Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models","volume":"32","author":"Sontag","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0215","article-title":"Preconditioning of mesenchymal stem cells by sevoflurane to improve their therapeutic potential","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0220","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/npp.2010.97","article-title":"The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms","volume":"35","author":"Tsai","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0225","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1161\/STROKEAHA.110.612788","article-title":"Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model","volume":"42","author":"Tsai","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003799","article-title":"PGC-1\u03b1 rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function","volume":"4","author":"Tsunemi","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0235","first-page":"419","article-title":"Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage","volume":"68","author":"van Velthoven","year":"2010","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0240","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/mt.2013.260","article-title":"Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage","volume":"22","author":"van Velthoven","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1242\/dmm.001198","article-title":"Progenitor cell therapies for traumatic brain injury: Barriers and opportunities in translation","volume":"2","author":"Walker","year":"2009","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0250","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.nbd.2012.03.002","article-title":"Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats","volume":"46","author":"Wei","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0255","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3727\/096368912X657251","article-title":"Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice","volume":"22","author":"Wei","year":"2013","journal-title":"Cell Transplant."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0260","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000142","article-title":"Intranasal delivery of neural stem cells: a CNS-specific, non-invasive cell-based therapy for experimental autoimmune encephalomyelitis","volume":"4","author":"Wu","year":"2013","journal-title":"J. Clin. Cell Immunol."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0265","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/JAD-122419","article-title":"Brain transit and ameliorative effects of intranasally delivered anti-amyloid-\u03b2 oligomer antibody in 5XFAD mice","volume":"35","author":"Xiao","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.expneurol.2016.04.003_bb0270","first-page":"298","article-title":"Angiogenesis, neurogenesis and brain recovery of function following injury","volume":"11","author":"Xiong","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.expneurol.2016.04.003_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082997","article-title":"Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488616300826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488616300826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T15:43:48Z","timestamp":1567784628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488616300826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":55,"alternative-id":["S0014488616300826"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2016.04.003","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2016.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}